Bieniek S A, Ownby R L, Penalver A, Dominguez R A
Department of Psychiatry and Behavioral Sciences, University of Miami, School of Medicine, FL, USA.
Pharmacotherapy. 1998 Jan-Feb;18(1):57-62.
To compare the utility of intramuscular lorazepam (LZ) with the combination of intramuscular haloperidol (HDL) and LZ to control acutely agitated behavior.
Randomized double-blind comparison.
Psychiatric emergency service of a large, university-affiliated, municipal hospital.
Twenty subjects treated on the psychiatric emergency service.
Patients received an injection of either LZ 2 mg (11 patients) or HDL 5 mg plus LZ 2 mg (9 patients). The Overt Aggression Scale (OAS), visual analog scales reflecting agitation and hostility, and the Clinical Global Impressions (CGI) severity scale were administered at baseline and 30, 60, 120, and 180 minutes after the injection.
Planned data comparisons included categoric assignment of patients as improved, as defined by decreases in outcome measures 60 minutes after the injection, as well as continuous variables up to 180 minutes after the injection. A significantly greater percentage of subjects receiving combined treatment improved on the specific measures 60 minutes after dosing (p<0.05). Kaplan-Meier survival analyses showed significant between-group differences in survival curves plotted for the entire study period (p<0.05). Repeated measures analyses of variance studying group differences showed that both groups improved over time, but between-group differences were not significant. The powers of these analyses were low due to the small sample. No serious adverse effects occurred in either treatment group.
Our results suggest superior efficacy for HDL-LZ over LZ alone. Categoric tests of improvement at 60 minutes provided the strongest evidence of group differences.
比较肌内注射劳拉西泮(LZ)与肌内注射氟哌啶醇(HDL)联合LZ控制急性激越行为的效用。
随机双盲对照研究。
一所大型大学附属医院的精神科急诊室。
20名在精神科急诊室接受治疗的患者。
患者分别接受2mg LZ注射(11例患者)或5mg HDL加2mg LZ注射(9例患者)。在基线时以及注射后30、60、120和180分钟使用外显攻击量表(OAS)、反映激越和敌意的视觉模拟量表以及临床总体印象(CGI)严重程度量表进行评估。
计划的数据比较包括根据注射后60分钟结局指标的下降情况将患者分类为病情改善,以及直至注射后180分钟的连续变量。接受联合治疗的受试者在给药后60分钟的特定指标上病情改善的比例显著更高(p<0.05)。Kaplan-Meier生存分析显示,在整个研究期间绘制的生存曲线存在显著的组间差异(p<0.05)。研究组间差异的重复测量方差分析表明,两组均随时间改善,但组间差异不显著。由于样本量小,这些分析的效能较低。两个治疗组均未发生严重不良反应。
我们的结果表明,HDL-LZ联合用药的疗效优于单独使用LZ。60分钟时改善情况的分类测试提供了最有力的组间差异证据。